Business
Halberd Corporation Pursues Extracorporeal Radio Frequency Treatment Against Covid-19
Halberd Corporation Pursues Extracorporeal Radio Frequency Treatment Against Covid-19.
About this update from Halberd Corp.
[{"type":"text","content":"JACKSON CENTER, PA / ACCESSWIRE / December 17, 2020 / Halberd Corp. (OTC PINK:HALB) announced they are pursuing development of their latest treatment variation in the fight against COVID-19. Halberd's provisional patent application, "Method For Treating And Curing Covid-19 Infection By Utilizing Radio Frequency Extracorporeally To Eradicate The Virus," was filed last month. The procedure is designed to treat infected blood which has been dosed with a specific antibody compound and then exposed to tuned radio frequencies in an extracorporeal manner.The treatment methodology entails using a specifically created antibody conjugated with a radio frequency reactive (metallic) moiety which binds with the target antigen (SARS-COV-2 or any other identified virus or disease antigen) in an extracorporeal mixing chamber. The infected patient's blood would pass through the mixing chamber where the antibody-metallic moiety binds with target antigens in the blood. The conjugated antibody-antigen-metallic moiety compound would then be subjected to specifically tuned radio frequency (RF) signals designed to destroy the target antigen. Any residual material would be filtered from the blood before being returned to the patient. This conjugation-irradiation-filtration process would be conducted in real-time on a continuous flow basis, much like kidney dialysis.Dr. Mitchell S. Felder, inventor of this technology and consultant to Halberd Corporation's Scientific Advisory Board, stated, "I believe this methodology could be extremely successful in not only treating patients severely affected by COVID-19, but any number of blood-borne or cerebral spinal fluid afflictions and diseases."William A. Hartman, Chairman, President & CEO, added, "We have examined a number of extracorporeal treatment variations, and this one seems to have the most universal application. This process only requires that we create an antibody which has an affinity to the target antigen and can bind with the designed metallic moiety. Once fully developed, this methodology could theoretically end the possibility of any and all future infectious pandemics. This revolutionary technology is designed to preclude the possibility of any potential resistance by any infectious pathogen - tuberculosis, malaria, sepsis, etc."The details of the Ha...